Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (European Journal of Clinical Microbiology & Infectious Diseases, (2018), 37, 11, (2097-2106), 10.1007/s10096-018-3344-1)

  1. Vehreschild, M.J.G.T.
  2. Taori, S.
  3. Goldenberg, S.D.
  4. Thalhammer, F.
  5. Bouza, E.
  6. van Oene, J.
  7. Wetherill, G.
  8. Georgopali, A.
Revista:
European Journal of Clinical Microbiology and Infectious Diseases

ISSN: 1435-4373,  0934-9723

Año de publicación: 2019

Volumen: 38

Número: 1

Páginas: 199

Tipo: Errata

DOI: 10.1007/S10096-018-3410-8 GOOGLE SCHOLAR lock_openAcceso abierto editor
Fuente de los datos: Scopus